Sort   by:  
 Page size 
ProteomicsIncreased soluble HLA in COVID-19 present a disease-related, diverse immunopeptidome associated with T cell immunity
HLA-presented antigenic peptides are central components of T cell-based immunity in infectious disease. Beside HLA molecules on cell surfaces, soluble HLA molecules (sHLA) are released in the blood suggested to impact cellular immune responses. We demonstrated that sHLA levels were significantly inc...
ORGANISM(S): Homo sapiens (Human) 
2022-11-23 | PXD029567 | Pride
Covid-19 Immunopeptidome Soluble hla 
ProteomicsImmunoprecipitation methods impact the peptide repertoire in immunopeptidomics
T cell-based immunotherapies, which have become a promising treatment approach for cancer patients, rely on the identification of human leukocyte antigen (HLA)-presented peptides. Mass spectrometry-based immunopeptidomics is the state-of-the-art method for the identification of clinically relevant n...
ORGANISM(S): Homo sapiens (Human) 
2023-07-05 | PXD041804 | Pride
Hydrophobicity Mass spectrometry Immunotherapies Immunopeptidomics Immunoprecipitation Immunogenicity Hla peptides 
ProteomicsImmunopeptidomics-guided warehouse design for peptide-based immunotherapy in chronic lymphocytic leukemia
In recent years the clinical success of T cell-based immunotherapy approaches has revolutionized treatment of solid tumors and hematological malignancies. However, still some patients do not respond to available therapies at all, others for limited time only. A promising low side-effect approach is ...
ORGANISM(S): Homo sapiens (Human) 
2021-09-10 | PXD024871 | Pride
Cll Hla Peptide warehouse Immunopeptidome 
ProteomicsImmune surveillance of acute myeloid leukemia is mediated by HLA-presented antigens on leukemia progenitor cells
Persistent therapy-resistant leukemic progenitor cells (LPC) are a main cause of disease relapse and recurrence in acute myeloid leukemia (AML). Specific LPC-targeting therapies may thus improve treatment outcome of AML patients. We demonstrate that LPCs present human leukocyte antigen (HLA)-restric...
ORGANISM(S): Homo sapiens (Human) 
2023-08-23 | PXD038691 | Pride
Mass spectrometry Acute myeloid leukemia Immunotherapy Immunopeptidomics Leukemic progenitor cells Hla peptides 
ProteomicsUpstream open reading frames regulate proto-oncogene translation and encode HLA-presented immunogenic tumor antigens
Upstream open reading frames (uORFs) represent translational control elements within eukaryotic transcript leader sequences. Recent data showed that uORFs can encode for biologically active proteins and human leucocyte antigen (HLA)-presented peptides and suggest their potential role in cancer cell ...
ORGANISM(S): Homo sapiens (Human) 
2022-04-04 | PXD025716 | Pride
Cancer Uorf Immunotherapy Immunopeptidomics Hla peptides 
ProteomicsThe antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell–based immunotherapy
Direct analysis of HLA-presented antigens by mass spectrometry provides a comprehensive view on the antigenic landscape of different tissues/malignancies and enables the identification of novel, pathophysiologically relevant T-cell epitopes. Here, we present a systematic and comparative study of the...
ORGANISM(S): Homo sapiens (Human) 
2022-07-19 | PXD035324 | Pride
Human leukocyte antigens T-lymphocytes Mass spectrometry Immunotherapy Ligands Peptides Antigens Multiple myeloma 
ProteomicsThe HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy
Anti-leukemia immunity plays an important role for disease control and maintenance of tyrosine kinase inhibitor (TKI)-free remission in chronic myeloid leukemia (CML). Antigen-specific immunotherapy holds promise to strengthen immune control in CML, but requires the identification of CML-associated ...
ORGANISM(S): Homo sapiens (Human) 
2018-12-11 | PXD010450 | Pride
Mass spectrometry Chronic myeloid leukemia Immunopeptidome 
ProteomicsMapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy
Identification of physiologically relevant peptide vaccine targets calls for the direct analysis of the entirety of naturally presented human leukocyte antigen (HLA) ligands, termed the HLA ligandome. In this study, we implemented this direct approach using immunoprecipitation and mass spectrometry ...
ORGANISM(S): Homo sapiens (Human) 
2019-10-14 | PXD015748 | Pride
Acute myeloid leukemia Lc-msms 
ProteomicsPhase I study of immunopeptidome-guided personalized multi-peptide vaccines in chronic lymphocytic leukemia patients under BTK-inhibitor-based regimes
Cancer peptide vaccines hold promise as therapeutic approach, but their effectiveness has been hampered by lack of suitable antigens and the variability of HLA backgrounds among patients, which restricts their applicability.. We here introduce a novel warehouse concept for the construction of person...
ORGANISM(S): Homo sapiens (Human) 
2026-01-22 | PXD059004 | Pride
Human Cll Immunopeptidomics Lc-ms/ms 
ProteomicsThe oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma
The DNAJB1-PRKACA fusion transcript is the oncogenic driver in fibrolamellar hepatocellular carcinoma, a lethal disease lacking specific therapies. This study reports on the identification, characterization, and immunotherapeutic application of HLA-presented neoantigens specific for the DNAJB1-PRKAC...
ORGANISM(S): Homo sapiens (Human) 
2022-10-13 | PXD029882 | Pride
Cancer Hla ligands Mass spectrometry Fibrolamellar hepatocellular carcinoma Immunopeptidomics Fl-hcc 
Sort   by:  
 Page size